Comparison of the Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Two Groups of Patients with Benign and Malignant Salivary Gland Tumors

Articles in Press

Document Type : Original

Authors

1 Isfahan University of Medical Sciences, faculty of Medicine, Isfahan Iran.

2 Department of Otorhinolaryngology, Head and Neck Surgery, Kashani Hospital, School of Medicine, Isfahan University of Medical Sciences, Isfahan Iran.

10.22038/ijorl.2025.89668.4001

Abstract

Introduction:
The ratio of neutrophils to peripheral lymphocytes is an inflammatory marker, and, based on previous studies, this ratio is associated with poor survival in several cancers. This study was conducted to compare the neutrophils-to-lymphocytes ratio (NLR) and platelets-to-lymphocytes ratio (PLR) in two groups of patients with benign and malignant salivary gland tumors.
Materials and Methods:
This study was cross-sectional, comparing two groups of patients with benign and malignant salivary gland masses. During the last 6 years (from 2018 to 2024), 380 Patients with a definite diagnosis of salivary gland tumors were included in the study, and NLR and PLR data were obtained from pre-operation laboratory exams.
Results:
NLR and PLR were significantly higher on average than in benign masses (P<0.05). The best cut point was 2.24 for NLR (sensitivity: 78%, specificity: 80%) and 104.35 for PLR (sensitivity: 68%, specificity: 60%).
Conclusion:
NLR and PLR are easy, practical methods that provide valuable information for diagnosing, assessing severity, and predicting prognosis of various diseases, such as salivary gland masses.

Keywords

Main Subjects

References

  1. Skálová A, Hyrcza MD, Leivo I. Update from the 5th edition of the World Health Organization classification of head and neck tumors: salivary glands. Head and Neck Pathology. 2022;16(1):40-53.
  2. Barnes L, Eveson JW, Sidransky D, Reichart P. Pathology and genetics of head and neck tumours: IARC; 2005.
  3. Committeri U, Barone S, Salzano G, Arena A, Borriello G, Giovacchini F, et al. Support Tools in the Differential Diagnosis of Salivary Gland Tumors through Inflammatory Biomarkers and Radiomics Metrics: A Preliminary Study. Cancers. 2023; 15(6):1876.
  4. Ettl T, Schwarz-Furlan S, Gosau M, Reichert TE. Salivary gland carcinomas. Oral and maxillofacial surgery. 2012;16(3):267-83.
  5. Tunç O, Gönüldas B, Kanlıkama M. Systemic Inflammatory Markers as a Prognostic Factor in Parotid Gland Tumors. Cyprus Journal of Medical Sciences. 2021;6(2):171-6.
  6. Pusztaszeri MP, Faquin WC, editors. Update in salivary gland cytopathology: recent molecular advances and diagnostic applications. Seminars in Diagnostic Pathology; 2015: Elsevier.
  7. Schmidt RL, Hall BJ, Wilson AR, Layfield LJ. A systematic review and meta-analysis of the diagnostic accuracy of fine-needle aspiration cytology for parotid gland lesions. American journal of clinical pathology. 2011;136(1):45-59.
  8. Lee JJL, Tan HM, Chua DYS, Chung JGK, Nga ME. The Milan system for reporting salivary gland cytology: a retrospective analysis of 1384 cases in a tertiary Southeast Asian institution. Cancer Cytopathology. 2020;128(5):348-58.
  9. Assar S, Assar S, Mardanifard HA, Jaafari-Ashkavandi Z. Salivary Gland Tumors in Iran: A Systematic Review of 2870 Cases Based on the New WHO Classification. Iran J Pathol. 2023;18(1):1-11. doi: 10.30699/IJP.2023.559121.2942. Epub 2023 Mar 23. PMID: 37383154; PMCID: PMC10293605.
  10. Colella G, Cannavale R, Flamminio F, Foschini MP. Fine-needle aspiration cytology of salivary gland lesions: a systematic review. Journal of Oral and Maxillofacial Surgery. 2010; 68(9): 2146-53.
  11. Salgarelli AC, Capparè P, Bellini P, Collini M. Usefulness of fine-needle aspiration in parotid diagnostics. Oral and maxillofacial surgery. 2009;13(4):185-90.
  12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. nature. 2008; 454(7203):436-44.
  13. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70.
  14. Abbate V, Orabona GDA, Barone S, Troise S, Bonavolontà P, Pacella D, et al. Relevance of Inflammatory Biomarkers in Salivary Gland Cancers Management. Eurasian J Med Oncol. 2021; 5:311-7.
  15. Whiteside T. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008; 27(45):5904-12.
  16. De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nature reviews cancer. 2006; 6(1): 24-37.
  17. Lin S-W, Hensley SE, Tatsis N, Lasaro MO, Ertl HC. Recombinant adeno-associated virus vectors induce functionally impaired transgene product–specific CD8+ T cells in mice. The Journal of clinical investigation. 2007; 117(12): 3958-70.
  18. Kasprzak A. The role of tumor microenvironment cells in colorectal cancer (CRC) cachexia. International journal of molecular sciences. 2021;22(4):1565.
  19. Damar M, Dinç AE, Erdem D, Aydil U, Kizil Y, Eravcı FC, et al. Pretreatment neutrophil-lymphocyte ratio in salivary gland tumors is associated with malignancy. Otolaryngology–Head and Neck Surgery. 2016; 155(6):988-96.
  20. Hu B, Yang X-R, Xu Y, Sun Y-F, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clinical Cancer Research. 2014;20(23):6212-22.
  21. Mascarella MA, Mannard E, Silva SD, Zeitouni A. Neutrophil‐to‐lymphocyte ratio in head and neck cancer prognosis: a systematic review and meta‐analysis. Head & neck. 2018; 40(5):1091-100.
  22. Gao Y, Guo W, Cai S, Zhang F, Shao F, Zhang G, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. Journal of Cancer. 2019;10(14):3188.
  23. Kuzucu İ, Güler İ, Kum RO, Baklacı D, Özcan M. Increased neutrophil lymphocyte ratio and platelet lymphocyte ratio in malignant parotid tumors. Brazilian journal of otorhinolaryngology. 2020; 86:105-10.
  24. Cristofaro MG, Ferragina F, Staglianò S, Arrotta A, D'Amico M, Barca I. Prognostic Value of Systemic Inflammatory Markers in Malignant Tumors of Minor Salivary Glands: A Retrospective Analysis of a Single Center. Cancers (Basel). 2025 Apr 21;17(8):1373. doi: 10.3390/cancers17081373. PMID: 40282549; PMCID: PMC12026184.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1. Magdum DB, Kulkarni NA, Kavle PG, Paraye S, Pohankar PS, Giram AV. Salivary Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor of Oral Premalignant and Malignant Disorders: A Prospective Study. Cureus. 2024 Mar 16; 16(3): e56273. doi: 10.7759/cureus.56273. PMID: 38623101; PMCID: PMC11017949.
  2. Cheng G, Liu F, Niu X, Fang Q. Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients. Cancer Manag Res. 2019 Mar 21;11:2281-2286. doi: 10.2147/CMAR.S195413. PMID: 30962717; PMCID:
  3. Szilasi Z, Jósa V, Zrubka Z, Mezei T, Vass T, Merkel K, Helfferich F, Baranyai Z. Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Markers of Survival in Patients with Head and Neck Tumours-Results of a Retrospective Multicentric Study. Int J Environ Res Public Health. 2020 Mar 7;17(5):1742. doi: 10.3390/ ijerph 17051742. PMID: 32155982; PMCID: PMC 7084240.
  4. Lee RH, Truong A, Wu X, et al. The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembro- lizumab. Head & Neck. 2024; 46(1): 129-137. doi: 1002/ hed. 27565
  5. Bora A. Is the neutrophil-to-lymphocyte ratio a marker for differentiating between benign and malignant submandibular gland masses? Rev Assoc Med Bras (1992). 2023 Oct 27;69(11):e20230738. doi: 10.1590/1806-9282.20230738. PMID: 37909621; PMCID: PMC10610767.
Iranian Journal of Otorhinolaryngology

Articles in Press, Corrected Proof
Available Online from 25 December 2025

Files

Share

How to cite

Statistics